A case of chronic lymphocytic leukemia still taking etanercept for ankylosing spondylitis

The possible risk of hematologic malignancies in anti TNF users is a matter of debate. Whether associated with the drug or not, how to behave when a hematologic malignancy is discovered in the course of anti TNF treatment remains unanswered. Here we present a 66 year old male patient who had AS for...

Full description

Saved in:
Bibliographic Details
Published inActa reumatológica portuguesa Vol. 41; no. 1; pp. 90 - 91
Main Authors Kuşkonmaz, Ş M, Mercan, R, Ozturk, M A
Format Journal Article
LanguageEnglish
Published Portugal 01.01.2016
Subjects
Aged
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Etanercept - adverse effects
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - chemically induced
Male
Spondylitis, Ankylosing - drug therapy
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online AccessGet full text

Cover

More Information
Summary:The possible risk of hematologic malignancies in anti TNF users is a matter of debate. Whether associated with the drug or not, how to behave when a hematologic malignancy is discovered in the course of anti TNF treatment remains unanswered. Here we present a 66 year old male patient who had AS for 30 years and had been on etanercept for the last two years and who is diagnosed with B cell chronic lymphocytic leukemia (CLL) stage 1. The patient is still on etanercept for 5 years after the diagnosis without any progression in CLL.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0303-464X